Market Overview

Celgene Wins One Bull, Loses Another On Revlimid Potential

Celgene Wins One Bull, Loses Another On Revlimid Potential
Related CELG
The Daily Biotech Pulse: FDA Nod For Mallinckrodt's Pain Drug, AbbVie-Neurocrine Report Positive Elagolix Results
The Daily Biotech Pulse: Gilead's Q2, Syndax Breast Cancer Drug Setback, Synergy Pharma On Brink Of Default
Stocks That Fell to '-Year Lows in the Week of Nov. –6 (GuruFocus)

Celgene Corporation (NASDAQ: CELG) is down about 35 percent year-over-year, and as management resists challenges to critical Revlimid patents, analysts are at odds about where the stock could head from here.

The Ratings

Bernstein analyst Aaron Gal upgraded Celgene from Market-Perform to Outperform and cut the price target from $121 to $102.

Argus analyst David Toung downgraded the stock from Buy to Hold.

The Bull Thesis

By Bernstein’s assessment, Celgene’s current discounted cash flow reflects the worst possible outcome for the Revlimid trial — a result that could push the launch to April 2020. Gal expects a victory in the second half of 2019 or a settlement even earlier.

His bullishness is bolstered by Celgene’s potential to secure four significant, valuation-driving approvals in the next two years or, in the case that valuation remains depressed, to pursue governance or ownership changes.

“This is fundamentally a valuation call on a 'cliff' company,” Gal said in a Wednesday note. 

The Bear Thesis

Toung is less optimistic about Revlimid’s legal issues, which could increase share volatility with an adverse ruling.

“We remain concerned about the company’s overreliance on Revlimid (65 percent of revenue) and about setbacks in its product pipeline,” Toung said. “While Celgene has settled one legal challenge to its Revlimid patents, it continues to fight challenges from other potential generic competitors.”

His downgrade also accounts for a perceived drop in financial strength after Celgene took on more debt to fund acquisitions.

Price Action

Celgene shares were up 0.64 percent at $77.10 after the open Wednesday. 

Related Links:

Celgene Forges Oncology Partnership With Germany's Evotec

Analyst: Trump's 'Naming And Shaming' Campaign To Build Pharma Headline Risk

Latest Ratings for CELG

Oct 2018Cantor FitzgeraldInitiates Coverage OnOverweight
Jul 2018Morgan StanleyMaintainsEqual-WeightEqual-Weight
Jul 2018Morgan StanleyMaintainsEqual-WeightEqual-Weight

View More Analyst Ratings for CELG
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech Upgrades Downgrades Price Target Top Stories Analyst Ratings General Best of Benzinga


Related Articles (CELG)

View Comments and Join the Discussion!

Latest Ratings

CPAImperial CapitalDowngrades68.0
PRMWImperial CapitalInitiates Coverage On18.0
TGTKeyBancInitiates Coverage On110.0
QCOMMorgan StanleyUpgrades0.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Red Robin Gourmet Burgers Downgraded After Q1 Print Falls Short Of BTIG's Expectations

Comcast Prepared To Submit All-Cash Offer For Fox Assets